Table 2.
Kaplan-Meier survival analysis for study population.
| Overall Survival | N (%) | Median (months) | 1-year | 3-year | 5-year | P value |
|---|---|---|---|---|---|---|
| All1 | 59 (100) | 30 | 79% | 45% | 31% | N/A |
| Lung Primary | 29 (49) | 17 | 73% | 33% | 27% | 0.033 |
| Other Primary | 30 (51) | 47 | 86% | 60% | 38% | |
| Synchronous | 11 (19) | 14 | 64% | 21% | 21% | 0.028 |
| Metachronous | 48 (81) | 41 | 83% | 51% | 34% | |
| DFI <12 months2 | 9 (19) | 13 | 56% | 33% | 0% | 0.038 |
| DFI ≥12 months2 | 39 (81) | 41 | 90% | 56% | 39% | |
| Male | 32 (54) | 30 | 78% | 45% | 32% | 0.69 |
| Female | 27 (46) | 30 | 81% | 48% | 33% | |
| Oligometastatic | 8 (14) | 25 | 75% | 38% | 13% | 0.62 |
| Isolated | 51 (86) | 30 | 80% | 48% | 38% |
1
Total n excludes 2 perioperative deaths, and 1 patient lost to follow-up.
2
Proportion includes only patients with metachronous diagnosis (n=48).